Skip to content
Posted on March 31, 2023 by: acn

Ocumension Therapeutics Announces 2022 Annual Results

Voice of Asia | Singapore

Singapore News & Headlines, Press Releases & Events

Posted on March 31, 2023 by: acn

Ocumension Therapeutics Announces 2022 Annual Results

  • Home
  • SEAPRWire
  • EQS Newswire
  • ACN Newswire
  • JCN Newswire
  • Contact

Tag: 全人抗体小鼠平台。在此基础上,百奥赛图整合靶点发现、高通量抗体发现、抗体分子体内高通量筛选评价等全链条新药开发能力,创新发起全球首个大规模体内抗体发现筛选计划——「千鼠万抗」,针对人类疾病超过1000个潜在抗体药物靶点,进行规模化抗体开发。据了解,renmice

  • Home
  • 全人抗体小鼠平台。在此基础上,百奥赛图整合靶点发现、高通量抗体发现、抗体分子体内高通量筛选评价等全链条新药开发能力,创新发起全球首个大规模体内抗体发现筛选计划——「千鼠万抗」,针对人类疾病超过1000个潜在抗体药物靶点,进行规模化抗体开发。据了解,renmice
Posted on August 11, 2022 by: acn

打造全球新药发源地 百奥赛图冲刺基因编辑第一股

       

HONG KONG, Aug 11, 2022 – (亚太商讯 via SEAPRWire.com) – 随着生物技术的迅猛发展,创新药已成为医药行业的热门词汇,并催生出众多的创新药企。而这些药企大多有一个共同点,专…

Continue Reading

Categories

  • ACN Newswire
  • EQS Newswire
  • JCN Newswire
  • SEAPRWire

Recent Stories

  • Ocumension Therapeutics Announces 2022 Annual Results
  • VC Holdings Announces 2022 Annual Results
  • 嘉泓物流 (2130.HK) 公布2022全年业绩 收益按年增长4.3%至约27.9亿港元
  • 欧康维视公布2022年全年业绩
  • 汇盈控股公布2022全年业绩
  • 中国中车2022年经营业绩稳中向好
  • Honda: Notice of Change in Capital Structure of Hitachi Astemo including Capital Participation of JIC Capital
  • ESPRIT Announces Annual Results for FY 2022
  • Alltronics 2022 Profit Surges 61.6%, Driven by Robust Cost Control and Better Product Mix
  • Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
  • Baguio Green’s 2022 Net Profit* Increased by 3.2 times, Contracts On Hand Recorded a Historical High with a Surge of 67% to HK$3.6 billion
  • 华讯有效控制成本及提升产品组合 2022年溢利上升61.6%
  • 冠科美博(Apollomics Inc.)宣布完成和SPAC Maxpro合并,并在纳斯达克上市
  • 碧瑶绿色2022年度净利润*大增3.2倍 手头合约激增67%至约36亿 创历史新高
  • 提质升级,着眼未来 中远海控以历史最优业绩夯实转型发展基础

Menu

  • Home
  • About Us
  • Contact Us
  • Term of Use
  • RSS Feed

Links

  • YAHOO
  • NASDAQ
  • Bloomberg
  • Newswire
  • EastMud
  • AsiaEase
  • NetDace
  • HKBrowse
  • AccessTH
  • AseanTrend
Copyright © 2023 VOASA